Dr. Wu on Efficacy of Approved Agents in Colorectal Cancer
Jennifer Wu, MD, assistant professor of Medicine, Department of Medicine, Perlmutter Cancer Center, NYU Langone Medical Center, discusses the efficacy of regorafenib and TAS-102 for the treatment of patients with colorectal cancer.
Jennifer Wu, MD, assistant professor of Medicine, Department of Medicine, Perlmutter Cancer Center, NYU Langone Medical Center, discusses the efficacy of regorafenib and TAS-102 for the treatment of patients with colorectal cancer (CRC).
As a single agent, regorafenib has been shown to have an overall survival (OS) benefit in refractory patients with CRC. A second oral agent, TAS-102, has had an OS benefit in patients. Wu explains that patients who receive TAS-102 were pretreated with regorafenib.
These agents are chosen based on patient preference and prior patient experience. Sometimes, the drugs can be administered sequentially, Wu says.
<<<
